VERTEX PHARMACEUTIC
VERTEX PHARMACEUTIC operates in Diversified Metals & Mining.
VERTEX PHARMACEUTIC (VX1) - Total Liabilities
Latest total liabilities as of September 2024: €6.61 Billion EUR
Based on the latest financial reports, VERTEX PHARMACEUTIC (VX1) has total liabilities worth €6.61 Billion EUR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
VERTEX PHARMACEUTIC - Total Liabilities Trend (2016–2023)
This chart illustrates how VERTEX PHARMACEUTIC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
VERTEX PHARMACEUTIC Competitors by Total Liabilities
The table below lists competitors of VERTEX PHARMACEUTIC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asra Minerals Ltd
AU:ASR
|
Australia | AU$2.99 Million |
|
Trisula International Tbk
JK:TRIS
|
Indonesia | Rp534.62 Billion |
|
Carl Data Solutions Inc
OTCQB:CDTAF
|
USA | $2.33 Million |
|
Longvie SA
BA:LONG
|
Argentina | AR$16.05 Billion |
|
AHB Holdings Bhd
KLSE:7315
|
Malaysia | RM2.05 Million |
|
Wirtek A/S
CO:WIRTEK
|
Denmark | Dkr18.41 Million |
|
International Graphite Ltd
AU:IG6
|
Australia | AU$3.47 Million |
|
Uranium Valley Mines Ltd.
V:VZZ
|
Canada | CA$1.14 Million |
Liability Composition Analysis (2016–2023)
This chart breaks down VERTEX PHARMACEUTIC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VERTEX PHARMACEUTIC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VERTEX PHARMACEUTIC (2016–2023)
The table below shows the annual total liabilities of VERTEX PHARMACEUTIC from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €5.15 Billion | +21.51% |
| 2022-12-31 | €4.24 Billion | +27.18% |
| 2021-12-31 | €3.33 Billion | +8.73% |
| 2020-12-31 | €3.06 Billion | +37.25% |
| 2019-12-31 | €2.23 Billion | +23.34% |
| 2018-12-31 | €1.81 Billion | +20.42% |
| 2017-12-31 | €1.50 Billion | -3.52% |
| 2016-12-31 | €1.56 Billion | -- |